iCAD Appoints Andrew Sassine to Board of Directors

NASHUA, N.H., Dec. 9, 2015 (GLOBE NEWSWIRE) — iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that Andrew Sassine will be joining the iCAD Board of Directors effective immediately.Dr. Lawrence Howard, Chairman of the iCAD Board of Directors, said, “We are pleased to welcome Andy Sassine to the Board of Directors. He has strong experience analyzing and working directly with companies such as iCAD from his time as a small-cap portfolio manager and his current service on several healthcare company boards. He also has been an investor in iCAD for quite some time and has a comprehensive understanding of the Company’s business and markets, positioning him to bring a valuable perspective to the refinement and expansion of our strategic growth plans.”Mr. Sassine currently serves on the board of directors of two public companies in the healthcare sector and three private companies, two of which are in the healthcare sector. He previously served in various positions at Fidelity Investments from 1999 to 2012, including serving as portfolio manager for the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund, and the Fidelity Advisor International Small Cap Opportunities Fund.Mr. Sassine also serves on the Board of Advisors for the Henry B. Tippie College of Business at the University of Iowa and previously served on the Board of Trustees at the Clarke Schools for Hearing and Speech. Mr. Sassine earned a Bachelor of Arts degree from the University of Iowa and a Master’s degree in Business Administration from the Wharton School at the University of Pennsylvania.About iCAD, Inc.iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit www.icadmed.com or www.xoftinc.com.“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.For iCAD investor relations:
The Ruth Group
Zack Kubow


For iCAD media inquiries:
Berry & Company Public Relations, LLC
Lynn Granito, 212-253-8881